MAP2K7 and melanoma: We also confirmed that the PROG melanomas carrying the AKTQ79K or PIK3CAD350G/E545G mutations both displayed re-activation of MAPK activity, suggesting that PI3K/AKT activation may have contributed to the selection of additional events that conferred robust BRAF/MEK inhibitor resistance.